질병 생태계 및 예측 리포트

Report 2025년 7월 16일

Systemic Lupus Erythematosus – Current Treatment – Current Treatment: Physician Insights – Systemic Lupus Erythematosus (EU5)

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. Symptoms range from general malaise to serious CNS and renal manifestations…

north_east

Report 2025년 7월 14일

Breast Cancer – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of breast cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of breast…

north_east

Report 2025년 7월 14일

Breast Cancer – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of breast cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of breast…

north_east

Report 2025년 7월 10일

Dyslipidemia – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dyslipidemia for each country…

north_east

Report 2025년 7월 10일

Dyslipidemia – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the total and diagnosed prevalence of…

north_east

Report 2025년 7월 10일

Dyslipidemia – Epidemiology – Extrapolated Worldwide Coverage

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key dyslipidemia patient populations, covering 171 countries and more…

north_east

Report 2025년 7월 10일

Obesity – Current Treatment – Current Treatment: Physician Insights – GLP-1 receptor agonist products (US)

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s semaglutide SC (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have gained popularity in…

north_east

Report 2025년 7월 10일

Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 receptor agonist products (US)

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s semaglutide SC (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have gained popularity in…

north_east

Report 2025년 7월 10일

Dyslipidemia – Epidemiology – Asia Pacific

north_east

Report 2025년 7월 10일

GLP-1 receptor agonists – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s semaglutide SC (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have gained popularity in…

north_east

Report 2025년 7월 10일

Dyslipidemia – Epidemiology – Europe

north_east

Report 2025년 7월 10일

Dyslipidemia – Epidemiology – Emerging Markets

north_east

Product logins

Disease Landscape and Forecast 인사이트

Systemic Lupus Erythematosus – Current Treatment – Current Treatment: Physician Insights – Systemic Lupus Erythematosus (EU5)

Breast Cancer – Epidemiology – Mature Markets

Breast Cancer – Epidemiology – Emerging Markets

Dyslipidemia – Epidemiology – Mature Markets

Dyslipidemia – Epidemiology – Epidemiology Dashboard

Dyslipidemia – Epidemiology – Extrapolated Worldwide Coverage

Obesity – Current Treatment – Current Treatment: Physician Insights – GLP-1 receptor agonist products (US)

Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 receptor agonist products (US)

Dyslipidemia – Epidemiology – Asia Pacific

GLP-1 receptor agonists – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)

Dyslipidemia – Epidemiology – Europe

Dyslipidemia – Epidemiology – Emerging Markets

Follow us

Contact us